TCI Wealth Advisors’s Bellicum Pharmaceuticals, Inc. BLCM Stock Holding History

TCI Wealth Advisors’s Portfolio BLCM Stock Details BLCM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q2	–	Sell	-50	Closed	-$2K	–	1591
2019 Q1	$2K	Sell	50 -20	-29%	-$668	﹤0.01%	1113
2018 Q4	$2K	Buy	70 +40	+133%	+$1.77K	﹤0.01%	1091
2018 Q3	$2K	Sell	30 -20	-40%	-$1.35K	﹤0.01%	1108
2018 Q2	$4K	Buy	50 +10	+25%	+$779	﹤0.01%	889
2018 Q1	$3K	Sell	40 -10	-20%	-$755	﹤0.01%	896
2017 Q4	$4K	Sell	50 -10	-17%	-$981	﹤0.01%	860
2017 Q3	$7K	Buy	60 +10	+20%	+$1.05K	﹤0.01%	679
2017 Q2	$6K	Sell	50 -10	-17%	-$1.24K	﹤0.01%	731
2017 Q1	$7K	Buy	60 +50	+500%	+$6.55K	﹤0.01%	665
2016 Q4	$1K	Buy	+10	New	+$1.77K	﹤0.01%	1270

Other funds holding BLCM

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Frazier Management Seattle, Washington $1.12M AUM 151.58% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

TCI Wealth Advisors's BLCM Position: Q2 2019 in Review

TCI Wealth Advisors sold out of Bellicum Pharmaceuticals, Inc. (BLCM) in Q2 2019, closing a stake of 50 shares — an estimated $2K sold.

TCI Wealth Advisors first reported a position in BLCM in Q4 2016 and held it in 10 quarters. The position peaked at $7K in Q3 2017. 79 funds tracked by Wall St. Rank hold BLCM as of Q2 2019.

TCI Wealth Advisors reported no remaining Bellicum Pharmaceuticals, Inc. position as of Q2 2019 after selling out during the quarter.
TCI Wealth Advisors sold 50 Bellicum Pharmaceuticals, Inc. shares in Q2 2019, an estimated $2K.
TCI Wealth Advisors first reported a position in Bellicum Pharmaceuticals, Inc. in Q4 2016 and held it in 10 quarters.
TCI Wealth Advisors's Bellicum Pharmaceuticals, Inc. position peaked at $7K in Q3 2017.
79 funds tracked by Wall St. Rank held Bellicum Pharmaceuticals, Inc. as of Q2 2019.

Based on TCI Wealth Advisors's 13F filing for Q2 2019, filed 23 Jul 2019.